SAM
MRNA icon

Sycomore Asset Management’s Moderna MRNA Stock Holding History

Sycomore Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-46,332
Closed -$4.67M – 78
2023
Q4 		$4.67M Buy
+46,332
New +$3.9M 1% 33

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sycomore Asset Management's MRNA Position: Q1 2024 in Review

Sycomore Asset Management sold out of Moderna (MRNA) in Q1 2024, closing a stake of 46,332 shares — an estimated $4.67M sold.

Sycomore Asset Management first reported a position in MRNA in Q4 2023 and held it in 1 quarter. The position peaked at $4.67M in Q4 2023. 903 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Sycomore Asset Management reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • Sycomore Asset Management sold 46,332 Moderna shares in Q1 2024, an estimated $4.67M.
  • Sycomore Asset Management first reported a position in Moderna in Q4 2023 and held it in 1 quarter.
  • Sycomore Asset Management's Moderna position peaked at $4.67M in Q4 2023.
  • 903 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Sycomore Asset Management's 13F filing for Q1 2024, filed 29 Apr 2024.